CXCL3 and renal cell adenocarcinoma: In 2024, Wang et al. discovered that CAFs could secrete CXCL3 and activate its receptor CXCR2 on RCC, resulting in the activation of the downstream ERK1/2 signaling pathway, thus promoting RCC sunitinib resistance[103].